MX370338B - Composicion farmaceutica de derivado de aminodihidrotiazina condensado. - Google Patents

Composicion farmaceutica de derivado de aminodihidrotiazina condensado.

Info

Publication number
MX370338B
MX370338B MX2017004418A MX2017004418A MX370338B MX 370338 B MX370338 B MX 370338B MX 2017004418 A MX2017004418 A MX 2017004418A MX 2017004418 A MX2017004418 A MX 2017004418A MX 370338 B MX370338 B MX 370338B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
fused aminodihydrothiazine
aminodihydrothiazine derivative
derivative
fused
Prior art date
Application number
MX2017004418A
Other languages
English (en)
Other versions
MX2017004418A (es
Inventor
Zaima Yasuhiro
Kazama Kazuo
Arase Shuntaro
NAGANE Kentaro
Horie Kanta
Ueki Yosuke
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2017004418A publication Critical patent/MX2017004418A/es
Publication of MX370338B publication Critical patent/MX370338B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

La presente invención proporciona una composición farmacéutica que comprende un compuesto representado por la fórmula (1): (ver Fórmula) o N-[3-((4aS,5R,7aS)-2-amino-5-metil-4a,5,7,7a-tetrahidro -4H-furo[3,4-d] [1,3]tiazin-7a-il)-4-fluorofenil)-5-difluorometilp irazin-2-carboxamida, o una sal farmacéuticamente aceptable del anterior, y una sal de un compuesto que tiene un grupo hidrocarbonado alifático saturado C12-22.
MX2017004418A 2014-10-10 2015-10-08 Composicion farmaceutica de derivado de aminodihidrotiazina condensado. MX370338B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014209289 2014-10-10
PCT/JP2015/078688 WO2016056638A1 (ja) 2014-10-10 2015-10-08 縮合アミノジヒドロチアジン誘導体の医薬組成物

Publications (2)

Publication Number Publication Date
MX2017004418A MX2017004418A (es) 2017-06-26
MX370338B true MX370338B (es) 2019-12-10

Family

ID=55653242

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004418A MX370338B (es) 2014-10-10 2015-10-08 Composicion farmaceutica de derivado de aminodihidrotiazina condensado.

Country Status (14)

Country Link
US (1) US10117876B2 (es)
EP (1) EP3205343B1 (es)
JP (3) JP6590822B2 (es)
KR (1) KR102524217B1 (es)
CN (1) CN107106568B (es)
AU (1) AU2015329027B2 (es)
BR (1) BR112017007293B1 (es)
CA (1) CA2963761C (es)
ES (1) ES2909797T3 (es)
IL (1) IL251559B (es)
MX (1) MX370338B (es)
RU (1) RU2710227C2 (es)
SG (1) SG11201702632QA (es)
WO (1) WO2016056638A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102524217B1 (ko) * 2014-10-10 2023-04-21 에자이 알앤드디 매니지먼트 가부시키가이샤 축합 아미노디하이드로티아진 유도체의 의약 조성물
SG10201913049QA (en) * 2016-10-27 2020-02-27 Eisai R&D Man Co Ltd Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease
JP6326114B2 (ja) * 2016-11-01 2018-05-16 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964779B1 (en) * 1998-04-08 2005-11-15 Kyowa Hakko Kogyo Co., Ltd. Tablet manufacturing method and tablet
DE602005018387D1 (de) * 2004-10-06 2010-01-28 Eisai R&D Man Co Ltd Medizinische zusammensetzung, verfahren zu ihrer hdihydropyridin-verbindung in einer medizinischen zusammensetzung
JP5158922B2 (ja) * 2006-02-24 2013-03-06 塩野義製薬株式会社 ビタミンｂ１２類含有組成物
CA2711655C (en) 2008-01-18 2013-03-05 Eisai R&D Management Co., Ltd. Condensed aminodihydrothiazine derivative
WO2009101940A1 (ja) * 2008-02-11 2009-08-20 Dainippon Sumitomo Pharma Co., Ltd. 溶出性の改善された錠剤
BR112013016241A2 (pt) * 2011-01-21 2016-07-12 Eisai R&D Man Co Ltd composto, e, método para fabricar um composto
JP2014037356A (ja) * 2012-08-13 2014-02-27 Takada Seiyaku Kk カンデサルタンシレキセチル経口製剤
US20140271911A1 (en) * 2014-03-26 2014-09-18 James Wallace Lithium and a beta-secretase inhibitor for the treatment of alzheimer's disease
KR102524217B1 (ko) * 2014-10-10 2023-04-21 에자이 알앤드디 매니지먼트 가부시키가이샤 축합 아미노디하이드로티아진 유도체의 의약 조성물

Also Published As

Publication number Publication date
CA2963761C (en) 2023-10-17
IL251559A0 (en) 2017-05-29
CN107106568A (zh) 2017-08-29
BR112017007293A2 (pt) 2017-12-26
CA2963761A1 (en) 2016-04-14
US10117876B2 (en) 2018-11-06
SG11201702632QA (en) 2017-05-30
IL251559B (en) 2021-02-28
RU2017111801A3 (es) 2019-02-12
JP2020125330A (ja) 2020-08-20
JPWO2016056638A1 (ja) 2017-07-20
KR20170066397A (ko) 2017-06-14
EP3205343A4 (en) 2018-06-06
RU2017111801A (ru) 2018-11-13
MX2017004418A (es) 2017-06-26
CN107106568B (zh) 2023-09-26
JP6590822B2 (ja) 2019-10-16
KR102524217B1 (ko) 2023-04-21
RU2710227C2 (ru) 2019-12-25
AU2015329027A1 (en) 2017-04-27
ES2909797T3 (es) 2022-05-10
US20180263998A1 (en) 2018-09-20
EP3205343A1 (en) 2017-08-16
AU2015329027B2 (en) 2020-04-30
WO2016056638A1 (ja) 2016-04-14
JP2019196395A (ja) 2019-11-14
EP3205343B1 (en) 2022-01-26
BR112017007293B1 (pt) 2022-12-13

Similar Documents

Publication Publication Date Title
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
WO2016011390A8 (en) Irak4 inhibiting agents
PH12018500061A1 (en) Oxysterols and methods of use thereof
WO2016079751A3 (en) A process for preparation of vortioxetine and polymorphs thereof
MX362383B (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
MA39956A (fr) Analogues du benzomorphane et leur utilisation
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
MY182884A (en) Pyrazole-amide compound and medicinal uses therefor
MX2019003724A (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
PH12016501517B1 (en) Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
MX366820B (es) Moduladores de gpr120 del acido biciclo[2.2.2].
MX2015015562A (es) Dihidropiridinona como inhibidores de monoacilglicerol aciltransferasa 2.
MX2016015247A (es) Derivados de benceno-sulfonamida y su uso como moduladores del receptor c huerfano relacionado a acido retinoico (rorc).
PH12018500903A1 (en) Pyranodipyridine compound
PH12016502246A1 (en) Carboxamide derivatives
EA201692298A1 (ru) Производные карбоксамидов
MX2015011375A (es) Moduladores del receptor acoplado a proteina-g 120 (gpr120) de acido biciclo-[2.2.1].
WO2018039077A8 (en) Therapeutic compounds
MX370338B (es) Composicion farmaceutica de derivado de aminodihidrotiazina condensado.
WO2015191681A3 (en) Substituted pyridinones as mgat2 inhibitors
EA201691741A1 (ru) Фармацевтическая композиция
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
MY176508A (en) Anti-enterovirus 71 thiadiazolidine derivative

Legal Events

Date Code Title Description
FG Grant or registration